. 2019 Apr 12;17:37. doi: 10.1186/s12958-019-0479-6

Table 1.

Comparison of clinical characteristics and IVF outcome between the OHSS and non-OHSS groups

Variable	OHSS group (n = 26)	Non-OHSS group (n = 31)	P value
Age of patients (y)	29.39 ± 2.56	28.94 ± 4.04	0.613
BMI (kg/m²)	23.25 ± 2.80	23.40 ± 2.91	0.842
Infertility duration(y)	3.62 ± 2.61	3.81 ± 2.66	0.786
Basal serum FSH (mIU/ml)	6.20 ± 1.10	6.93 ± 1.76	0.074
Basal serum LH (mIU/ml)	6.81 ± 5.07	4.26 ± 1.67	0.020^a
Basal serum E2 (pg/ml)	29.45(21.39–34.61)	25.02(13.35–39.62)	0.671
Basal serum P4 (ng/ml)	0.57(0.38–0.79)	0.54(0.38–0.67)	0.414
Basal serum PRL (ng/ml)	18.24 ± 7.56	18.21 ± 7.94	0.986
Basal serum T (ng/ml)	0.31 ± 0.16	0.25 ± 0.13	0.279
Antral follicle count(n.)	16.89 ± 4.97	13.26 ± 4.75	0.146
Starting dose of Gonadotrophin (IU)	150(112.5–150)	150(112.5–225)	0.174
Gonadotrophin duration (d)	11.54 ± 1.30	10.77 ± 1.91	0.089
Total Gonadotrophin dose (IU)	1425.00(1190.63–1678.13)	1500(1275.00–2125.00)	0.248
Serum E2 on hCG day (pg/ml)	7667.46 ± 2821.10	4076.58 ± 2343.74	<0.001^a
Serum P4 on hCG day (ng/ml)	1.10 ± 0.42	0.69 ± 0.33	<0.001^a
Serum E2 on OPU day (pg/ml)	4306.81 ± 1683.73	2402.39 ± 1666.98	<0.001 ^a
Serum P4 on OPU day (ng/ml)	22.65(11.97–34.61)	7.28(5.37–12.08)	<0.001 ^a
Larger than 18 mm before injection (n.)	4(3–5)	4(3–5.25)	0.201
Total oocytes obtained (n.)	20.46 ± 5.83	10.36 ± 4.87	<0.001^a
No. of 2PN oocytes	14.15 ± 5.49	7.58 ± 4.07	<0.001^a
No. of 2PN cleavage embryos	13.65 ± 5.11	7.48 ± 4.12	<0.001^a
High-quality embryos (n.)	6.31 ± 3.00	3.45 ± 2.50	<0.001 ^a
2PN oocytes ratio	0.74 ± 0.04	0.69 ± 0.03	0.351
2PN cleavage embryos ratio	0.72 ± 0.04	0.67 ± 0.03	0.32
Total embryos ratio	0.37 ± 0.03	0.42 ± 0.04	0.245
High-quality embryos ratio	0.35 ± 0.04	0.32 ± 0.03	0.596
FF melatonin(ng/ml)	35.94 ± 10.18	23.93 ± 10.94	<0.001^a

^aP < 0.05 was considered statistically significant